
Parmax Pharma Ltd Falls to 52-Week Low of Rs 24.5 Amidst Continued Weakness
2026-03-18 10:04:09Parmax Pharma Ltd, a micro-cap entity in the Pharmaceuticals & Biotechnology sector, has declined sharply to a new 52-week low of Rs.24.5, marking a significant drop of 11.71% in today’s trading session. This fresh low underscores the stock’s ongoing underperformance relative to its sector and broader market indices.
Read full news article
Parmax Pharma Ltd Falls to 52-Week Low of Rs 25 Amidst Weak Financials
2026-03-12 14:57:13Parmax Pharma Ltd’s shares declined sharply to a new 52-week low of Rs.25 on 12 Mar 2026, marking a significant downturn amid ongoing financial headwinds and sector underperformance. The stock’s recent volatility and sustained downward trend reflect persistent challenges in the company’s financial metrics and market positioning.
Read full news article
Parmax Pharma Q3 FY26: Mounting Losses Deepen as Revenue Plummets 72% YoY
2026-02-16 22:05:05Parmax Pharma Ltd., a micro-cap pharmaceutical company specialising in Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO), has reported deeply concerning financial results for Q3 FY26, with net losses widening to ₹0.73 crores whilst revenues collapsed 72.74% year-on-year to ₹2.53 crores. The company, trading at ₹32.00 with a market capitalisation of just ₹12.00 crores, has now recorded consecutive quarterly losses throughout FY26, raising serious questions about operational viability and management execution.
Read full news articleClosure of Trading Window
30-Mar-2026 | Source : BSEClosure of trading window
Appointment of Company Secretary and Compliance Officer
25-Mar-2026 | Source : BSEAppointment of Ms. Bhakti Aghera as a Company Secretary
Board Meeting Outcome for Outcome Of Board Meeting
14-Feb-2026 | Source : BSEOutcome of Board meeting for Financial Results
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available







